Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Zentalis Pharmaceuticals has received an average rating of "Moderate Buy" from five brokerage firms, with an average target price of $5.84 for the stock.
• The company's stock opened at $1.52 and has seen a trading increase of 1.3%, while experiencing a 12-month low of $1.01.
• Zentalis recently reported an earnings per share (EPS) of ($0.37), surpassing analysts' expectations of ($0.56) by $0.19.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $5.84.

A number of research analysts have issued reports on ZNTL shares. Wall Street Zen raised Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. HC Wainwright raised Zentalis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 7th. Finally, Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th.

Zentalis Pharmaceuticals Trading Up 1.3%

NASDAQ ZNTL opened at $1.52 on Thursday. The stock has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $1.45. The company has a market capitalization of $109.65 million, a PE ratio of -0.67 and a beta of 1.76. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.19. As a group, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Millennium Management LLC grew its stake in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock valued at $4,881,000 after acquiring an additional 2,111,951 shares during the period. Acadian Asset Management LLC grew its stake in Zentalis Pharmaceuticals by 150.6% in the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company's stock valued at $4,244,000 after acquiring an additional 1,606,802 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth about $1,126,000. Peapod Lane Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals during the first quarter worth about $888,000. Finally, Tybourne Capital Management HK Ltd. boosted its position in shares of Zentalis Pharmaceuticals by 53.7% during the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company's stock worth $1,715,000 after buying an additional 516,666 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.